

**EISNERAMPER**

**CANCER RESEARCH INSTITUTE, INC.**

**FINANCIAL STATEMENTS**

**JUNE 30, 2020 and 2019**



# CANCER RESEARCH INSTITUTE, INC.

## Contents

	<u>Page</u>
<b>Independent Auditors' Report</b>	1
<b>Financial Statements</b>	
Statements of financial position as of June 30, 2020 and 2019	2
Statements of activities for the years ended June 30, 2020 and 2019	3
Statement of functional expenses for the year ended June 30, 2020 (with summarized financial information in 2019)	4
Statement of functional expenses for the year ended June 30, 2019	5
Statements of cash flows for the years ended June 30, 2020 and 2019	6
Notes to financial statements	7

## INDEPENDENT AUDITORS' REPORT

Board of Trustees  
Cancer Research Institute, Inc.

### Report on the Financial Statements

We have audited the accompanying financial statements of the Cancer Research Institute, Inc. (the "Institute"), which comprise the statements of financial position as of June 30, 2020 and 2019, and the related statements of activities, functional expenses, and cash flows for each of the years then ended, and the related notes to the financial statements.

### *Management's Responsibility for the Financial Statements*

The Institute's management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### *Auditor's Responsibility*

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### *Opinion*

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Cancer Research Institute, Inc. as of June 30, 2020 and 2019, and the changes in its net assets and its cash flows for each of the years then ended, in accordance with accounting principles generally accepted in the United States of America.



EISNERAMPER LLP  
New York, New York  
November 5, 2020



# CANCER RESEARCH INSTITUTE, INC.

## Statements of Financial Position

	June 30,	
	<u>2020</u>	<u>2019</u>
<b>ASSETS</b>		
Cash and cash equivalents	\$ 29,455,207	\$ 27,429,143
Contributions and grants receivable, net	37,424,255	40,821,074
Bequests receivable	86,655	330,714
Other receivables	233,807	287,139
Investments	58,149,198	57,410,532
Property and equipment, net	162,580	188,896
Prepaid expenses and other assets	398,680	484,257
Beneficial interest in perpetual trust	<u>653,814</u>	<u>656,339</u>
	<b><u>\$ 126,564,196</u></b>	<b><u>\$ 127,608,094</u></b>
<b>LIABILITIES AND NET ASSETS</b>		
Liabilities:		
Accounts payable and accrued expenses	\$ 444,287	\$ 565,250
Paycheck Protection Program loan payable	710,150	-
Annuities payable	47,722	77,291
Grants and fellowships payable, net	64,875,092	68,004,733
Deferred rent obligation	120,803	130,936
Refundable deposit	<u>31,541</u>	<u>31,541</u>
Total liabilities	<b><u>66,229,595</u></b>	<b><u>68,809,751</u></b>
Commitments and other uncertainty (see Notes C and N)		
Net assets:		
Without donor restrictions:		
Undesignated and available for general activities	31,513,552	29,939,479
Board-designated as endowment	<u>4,539,701</u>	<u>4,428,807</u>
Total net assets without donor restrictions	<b><u>36,053,253</u></b>	<b><u>34,368,286</u></b>
With donor restrictions:		
Purpose restrictions	20,749,144	20,895,328
Perpetual in nature	<u>3,532,204</u>	<u>3,534,729</u>
Total net assets with donor restrictions	<b><u>24,281,348</u></b>	<b><u>24,430,057</u></b>
Total net assets	<b><u>60,334,601</u></b>	<b><u>58,798,343</u></b>
	<b><u>\$ 126,564,196</u></b>	<b><u>\$ 127,608,094</u></b>

# CANCER RESEARCH INSTITUTE, INC.

## Statements of Activities

	Year Ended June 30,					
	2020			2019		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
<b>Operating support and revenues:</b>						
Public support:						
General and trustee	\$ 8,198,754	\$ -	\$ 8,198,754	\$ 7,379,565	\$ -	\$ 7,379,565
Combined federal campaigns	423,479	-	423,479	415,069	100,000	515,069
Bequests and memorials	5,761,396	-	5,761,396	3,061,390	-	3,061,390
Special events (net of direct benefit to donors of \$127,550 in 2020 and \$256,236 in 2019)	1,565,196	15,008	1,580,204	2,248,880	12,272	2,261,152
Designated contributions (including in-kind contributions of services of \$564,130 in 2020 and \$484,799 in 2019)	15,687,115	4,169,891	19,857,006	17,150,730	10,493,483	27,644,213
Total public support	31,635,940	4,184,899	35,820,839	30,255,634	10,605,755	40,861,389
Operating revenues:						
Rental income (net of related expenses of \$132,810 in 2020 and 130,046 in 2019)	18,188	-	18,188	20,197	-	20,197
Investment income allocation	2,901,985	-	2,901,985	2,586,550	-	2,586,550
Miscellaneous	232,975	-	232,975	138,308	-	138,308
Total operating revenues	3,153,148	-	3,153,148	2,745,055	-	2,745,055
Net assets released from restrictions	4,331,083	(4,331,083)	-	6,378,118	(6,378,118)	-
Total operating support and revenues	39,120,171	(146,184)	38,973,987	39,378,807	4,227,637	43,606,444
<b>Operating expenses:</b>						
Program services:						
Science, medical and research information, and communications	3,910,236	-	3,910,236	5,187,507	-	5,187,507
Research	24,050,615	-	24,050,615	25,520,160	-	25,520,160
Total program services	27,960,851	-	27,960,851	30,707,667	-	30,707,667
Supporting services:						
Administration	1,546,492	-	1,546,492	1,471,774	-	1,471,774
Marketing and development	2,813,295	-	2,813,295	2,737,455	-	2,737,455
Allowance for uncollectible accounts	3,349,084	-	3,349,084	2,163,048	-	2,163,048
Total supporting services	7,708,871	-	7,708,871	6,372,277	-	6,372,277
Total expenses	35,669,722	-	35,669,722	37,079,944	-	37,079,944
Change in net assets from operating activities	3,450,449	(146,184)	3,304,265	2,298,863	4,227,637	6,526,500
<b>Non-operating activities:</b>						
Net investment (loss) income in excess of investment allocation	(1,765,482)	-	(1,765,482)	74,767	-	74,767
Change in value of perpetual trust	-	(2,525)	(2,525)	-	4,670	4,670
<b>Change in net assets</b>	1,684,967	(148,709)	1,536,258	2,373,630	4,232,307	6,605,937
Net assets, beginning of year	34,368,286	24,430,057	58,798,343	31,994,656	20,197,750	52,192,406
<b>Net assets, end of year</b>	\$ 36,053,253	\$ 24,281,348	\$ 60,334,601	\$ 34,368,286	\$ 24,430,057	\$ 58,798,343

See notes to financial statements.

# CANCER RESEARCH INSTITUTE, INC.

## Statement of Functional Expenses

Year Ended June 30, 2020

(with summarized financial information for 2019)

	Program Services			Support Services			Totals	
	Science, Medical and Research Information, and Communications	Research	Total	Administration	Marketing and Development	Total	2020	2019
Fellowship program	\$ -	\$ 5,720,957	\$ 5,720,957	\$ -	\$ -	\$ -	\$ 5,720,957	\$ 4,769,750
Designated grants program	-	1,692,560	1,692,560	-	-	-	1,692,560	928,667
Clinical accelerator program	-	6,995,498	6,995,498	-	-	-	6,995,498	10,371,973
Technology Prize Award	-	1,000,000	1,000,000	-	-	-	1,000,000	1,000,000
CLIP grants program	-	2,391,600	2,391,600	-	-	-	2,391,600	2,199,770
STAR Program	-	6,250,000	6,250,000	-	-	-	6,250,000	6,250,000
Salaries, benefits and related taxes	1,903,877	-	1,903,877	1,003,912	1,809,563	2,813,475	4,717,352	4,535,893
Professional fees and commissions	1,189,480	-	1,189,480	157,076	181,693	338,769	1,528,249	1,749,889
Printing, postage and supplies	178,940	-	178,940	136,261	334,613	470,874	649,814	586,066
Rent	193,560	-	193,560	238,585	160,557	399,142	592,702	575,047
Telephone	13,381	-	13,381	13,337	13,337	26,674	40,055	43,215
Advertising	53,341	-	53,341	1,289	203,859	205,148	258,489	397,298
Depreciation and amortization	16,126	-	16,126	8,781	15,006	23,787	39,913	39,540
Travel, catering, and related costs	344,648	-	344,648	19,683	210,020	229,703	574,351	1,703,302
Insurance expense	-	-	-	60,595	-	60,595	60,595	37,974
Miscellaneous	16,883	-	16,883	39,783	12,197	51,980	68,863	114,794
Total expenses before allowance for uncollectible accounts	3,910,236	24,050,615	27,960,851	1,679,302	2,940,845	4,620,147	32,580,998	35,303,178
Allowance for uncollectible accounts	-	-	-	3,349,084	-	3,349,084	3,349,084	2,163,048
Total expenses	3,910,236	24,050,615	27,960,851	5,028,386	2,940,845	7,969,231	35,930,082	37,466,226
Less:								
Direct benefit to donors	-	-	-	-	(127,550)	(127,550)	(127,550)	(256,236)
Rent	-	-	-	(132,810)	-	(132,810)	(132,810)	(130,046)
Total expenses per statements of activities	\$ 3,910,236	\$ 24,050,615	\$ 27,960,851	\$ 4,895,576	\$ 2,813,295	\$ 7,708,871	\$ 35,669,722	\$ 37,079,944

See notes to financial statements.

**CANCER RESEARCH INSTITUTE, INC.**

**Statement of Functional Expenses  
Year Ended June 30, 2019**

	Program Services			Support Services			Totals
	Science, Medical and Research Information, and Communications	Research	Total	Administration	Marketing and Development	Total	2019
Fellowship program	\$ -	\$ 4,769,750	\$ 4,769,750	\$ -	\$ -	\$ -	\$ 4,769,750
Designated grants program	-	928,667	928,667	-	-	-	928,667
Clinical accelerator program	-	10,371,973	10,371,973	-	-	-	10,371,973
Technology Prize Award	-	1,000,000	1,000,000	-	-	-	1,000,000
CLIP grants program	-	2,199,770	2,199,770	-	-	-	2,199,770
STAR Program	-	6,250,000	6,250,000	-	-	-	6,250,000
Salaries, benefits and related taxes	1,793,935	-	1,793,935	1,009,289	1,732,669	2,741,958	4,535,893
Professional fees and commissions	1,255,051	-	1,255,051	170,641	324,197	494,838	1,749,889
Printing, postage and supplies	207,308	-	207,308	67,403	311,355	378,758	586,066
Rent	187,306	-	187,306	232,396	155,345	387,741	575,047
Telephone	14,405	-	14,405	14,405	14,405	28,810	43,215
Advertising	301,072	-	301,072	449	95,777	96,226	397,298
Depreciation and amortization	15,380	-	15,380	9,094	15,066	24,160	39,540
Travel, catering, and related costs	1,372,567	-	1,372,567	10,960	319,775	330,735	1,703,302
Insurance expense	-	-	-	37,974	-	37,974	37,974
Miscellaneous	40,483	-	40,483	49,209	25,102	74,311	114,794
Total expenses before allowance for uncollectible accounts	5,187,507	25,520,160	30,707,667	1,601,820	2,993,691	4,595,511	35,303,178
Allowance for uncollectible accounts	-	-	-	2,163,048	-	2,163,048	2,163,048
Total expenses	5,187,507	25,520,160	30,707,667	3,764,868	2,993,691	6,758,559	37,466,226
Less:							
Direct benefit to donors	-	-	-	-	(256,236)	(256,236)	(256,236)
Rent	-	-	-	(130,046)	-	(130,046)	(130,046)
Total expenses per statements of activities	<u>\$ 5,187,507</u>	<u>\$ 25,520,160</u>	<u>\$ 30,707,667</u>	<u>\$ 3,634,822</u>	<u>\$ 2,737,455</u>	<u>\$ 6,372,277</u>	<u>\$ 37,079,944</u>

See notes to financial statements.

**CANCER RESEARCH INSTITUTE, INC.****Statements of Cash Flows**

	Year Ended June 30,	
	<u>2020</u>	<u>2019</u>
<b>Cash flows from operating activities:</b>		
Change in net assets	\$ 1,536,258	\$ 6,605,937
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Donated securities	(259,450)	(139,340)
Proceeds from sale of donated securities	258,534	137,039
Depreciation and amortization	39,913	39,540
Allowance for uncollectible accounts	3,349,084	2,163,048
Net realized and unrealized gains on investments	(979,792)	(2,578,661)
Change in value of beneficial interest in perpetual trust	2,525	(4,670)
Deferred rent	(10,133)	(10,133)
Changes in:		
Contributions and grants receivable, net	47,735	(9,566,257)
Bequests receivable	244,059	332,609
Other receivables	53,332	2,538
Prepaid expenses and other assets	85,577	(69,993)
Accounts payable and accrued expenses	(150,532)	116,039
Grants and fellowships payable	(3,129,641)	9,095,588
Refundable deposits	-	(18,400)
	<u>1,087,469</u>	<u>6,104,884</u>
Net cash provided by operating activities		
<b>Cash flows from investing activities:</b>		
Purchases of office equipment	(13,597)	(17,375)
Purchases of long-term investments	(14,999,938)	(6,981,283)
Proceeds from sales of long-term investments	<u>15,241,980</u>	<u>6,947,705</u>
Net cash provided by in investing activities	<u>228,445</u>	<u>(50,953)</u>
<b>Cash flows from financing activities:</b>		
Proceeds from Paycheck Protection Program loan payable	<u>710,150</u>	-
<b>Net increase in cash and cash equivalents</b>	<b>2,026,064</b>	<b>6,053,931</b>
Cash and cash equivalents, beginning of year	<u>27,429,143</u>	<u>21,375,212</u>
<b>Cash and cash equivalents, end of year</b>	<b>\$ <u>29,455,207</u></b>	<b>\$ <u>27,429,143</u></b>
<b>Supplemental disclosure of cash flow information:</b>		
Donated services	<u>\$ 564,130</u>	<u>\$ 484,799</u>

*See notes to financial statements.*



## **CANCER RESEARCH INSTITUTE, INC.**

### **Notes to Financial Statements June 30, 2020 and 2019**

#### **NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES**

##### **[1] The Institute:**

The Cancer Research Institute, Inc. (the "Institute") was founded in 1953 in New York to foster the field of cancer immunology, in the belief that the body's immune system can be used to control and cure cancer. The Institute supports research with the immediate aim of increasing the understanding of the immune system and with the ultimate goal of developing immunological methods for the prevention and treatment of human cancer. The Institute also functions as a definitive source of public information on cancer immunology and cancer treatment.

The Institute is a not-for-profit corporation exempt from federal income taxes pursuant to Section 501(c)(3) of the U.S. Internal Revenue Code (the "Code") and from state and local taxes under comparable laws.

##### **[2] Basis of accounting:**

The financial statements of the Institute have been prepared using the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") as applicable to not-for-profit organizations.

##### **[3] Use of estimates:**

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, public support and revenues and expenses, as well as the disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

##### **[4] Operating measure:**

Operating revenues and expenses reflect the activities in which the Institute typically engages to fulfill its mission. The Institute utilizes a spending rate in making its annual investment allocation for support of operations. Investment income, including net realized and unrealized gains and losses, earned in excess of or less than the Institute's spending rate as well as the change in the value of perpetual trust is recognized as non-operating revenue.

##### **[5] Cash and cash equivalents:**

For financial-reporting purposes, the Institute considers all highly liquid instruments purchased with a maturity of three months or less, when purchased, to be cash equivalents, except for those cash equivalent assets held as part of the investment portfolio.

##### **[6] Investments:**

The Institute's investments in equity securities, mutual funds, fixed income securities, and exchange traded funds are reported at their fair values in the statements of financial position based on quoted market prices. Cash and cash equivalents held as part of the investment portfolio are also included in the balances reported as investments.

## CANCER RESEARCH INSTITUTE, INC.

### Notes to Financial Statements June 30, 2020 and 2019

#### NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### [6] Investments: (continued)

The Institute also has investments in limited partnerships and limited liability companies which are considered to be alternative investments, for which readily determinable fair values do not exist. The fair value of the alternative investments has been estimated based on the respective net asset value ("NAV") per share (or its equivalent unit) of each investment, as reported by the particular investment manager. Investments in limited partnerships and/or limited liability companies where NAV cannot be used as a practical expedient to fair value are valued based on the valuation policies and procedures of the general partners. The general partners perform oversight of the underlying positions, both on an investment level and from a risk perspective. The general partners are also responsible for ensuring that the investments are valued according to the policies and procedures adopted by the partnerships. The Institute places reliance upon those procedures, and it records those investments at fair value as determined by the general partners. Because of the complex management structures and nature of the underlying investments and the inherent uncertainty of the valuation of the alternative investments, the Institute's management and its various investment managers monitor their positions to reduce the risk of potential losses due to changes in fair values or the failure of counterparties to perform on a routine basis. Management believes the carrying amount of the investments in non-publicly traded securities is a reasonable estimate of their fair value. However, such estimated fair values may differ significantly from the values that would have been used had a ready market for these investments existed.

Certain of the Institute's investment managers enter into derivatives contracts held or issued for trading purposes. These investments are subject to various market risks, which arise from changes in securities values and other market conditions. As part of their overall trading strategies, the investment managers may engage in the purchases and sales of index and equity options, for the purpose of generating profit and/or reducing market risk. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

The Institute's investments, in general, are subject to various risks, such as interest-rate, market, and credit risks. Due to the level of risk associated with certain investment vehicles, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

Investment transactions are recorded on a trade-date basis. Realized gains and losses on investments sold, and unrealized appreciation and depreciation on investments held, are reported in the statements of activities as increases or decreases in net assets without donor restrictions unless their use is restricted through donor stipulation. Realized gains and losses on investments are determined by comparison of the cost basis to proceeds at the time of disposition. Distributions from limited partnerships and limited liability companies that represent returns of contributed capital reduce the cumulative costs basis of the respective investment. Distributions received from limited partnerships and limited liability companies in excess of the Institute's cumulative cost basis are recognized as realized gains. Unrealized gains and losses on investments are determined by comparing the investment's cost to the fair value at the end of each year. The earnings from dividends and interest are recognized when earned.

Donated securities are recorded at their estimated fair values, or by their net asset values as determined by the Institute's management on the dates of donation. The Institute's policy is to sell the donated securities immediately, and, accordingly, for purposes of the statement of cash flows, donated securities and the proceeds generated from their sale are included within operating activities. With respect to donors' contributions of equity securities, which for example, are: (i) not readily marketable, (ii) the securities of private companies, or (iii) the securities of companies in liquidation, the Institute's policy is to record such items at appraised value at time of donation in the absence of readily determinable fair values, although such assets may have significant value.

# CANCER RESEARCH INSTITUTE, INC.

## Notes to Financial Statements June 30, 2020 and 2019

### NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### [6] Investments: (continued)

Investment expenses include the services of bank trustees, investment managers and custodians. The balances of investment management fees disclosed in Note C are those specific fees charged by the Institute's various investment managers in each fiscal year; however, they do not include those fees that are embedded in various other investment accounts and transactions.

#### [7] Office equipment and leasehold improvements:

Office equipment and leasehold improvements are stated at their original costs at the dates of acquisition, or if contributed, at their fair values at the dates of donation, net of accumulated depreciation. The Institute capitalizes items of property and equipment that have a useful life greater than one year, whereas minor costs of repairs and maintenance are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of three to ten years. Leasehold improvements are recorded at cost and are amortized over the life of the lease.

Management evaluates the recoverability of the investment in long-lived assets on an on-going basis and recognizes any impairment in the year of determination. Long-lived assets were tested for impairment as of June 30, 2020 and 2019, respectively, and in the opinion of management, there were no impairments. It is reasonably possible that relevant conditions could change in the near term and necessitate a change in management's estimate of the recoverability of these assets.

#### [8] Beneficial interest in perpetual trust:

The Institute has been named as a beneficiary of a perpetual charitable trust which is administered by a third-party trustee. The trust was created independently by a donor and is administered by an outside agent designated by the donor; accordingly, the Institute has neither possession nor control over the assets of the trust.

The Institute reported the asset and recognized contribution revenue with donor restriction-perpetual in nature, at the fair value of the Institute's interest in the trust assets. Distributions received on the trust assets are reported as revenue without donor restrictions in the statements of activities, in accordance with donor intent. Subsequent changes in fair value of the perpetual trust assets are recorded as a change in the value of perpetual trust in net assets with donor restrictions.

#### [9] Deferred rent obligation:

Rent expense is recorded on a straight-line basis over the term of the lease, and includes any concession and rent escalations over the life of the lease agreement. The difference between rental payments made under the terms of the lease agreement and rent expense calculated on a straight-line basis is recorded as a deferred rent obligation in the statements of financial position.

#### [10] Accrued vacation:

Based on their tenure, the Institute's employees are entitled to be paid for unused vacation time if they leave the Institute's employ. Accordingly, at each fiscal year-end, the Institute must recognize a liability for the amount that would be incurred if employees with such unused vacation time were to leave. At June 30, 2020 and 2019, this accrued vacation obligation was approximately \$290,000 and \$240,000, respectively, which is included in accounts payable and accrued expenses in the statements of financial position.

## CANCER RESEARCH INSTITUTE, INC.

### Notes to Financial Statements June 30, 2020 and 2019

#### NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### [11] Paycheck Protection Program loan payable:

The Institute has elected to record the Paycheck Protection Program ("PPP") loan as a loan payable. Loan forgiveness will be recognized when the conditions for loan forgiveness are met and the forgiveness amount is formally approved by the bank and the U.S. Small Business Administration ("SBA") (see Note E).

##### [12] Functional allocation of expenses:

The costs of providing the Institute's various programs and supporting services have been summarized on a functional basis in the statements of functional expenses. Accordingly, direct costs have been functionalized within the program and supporting services based on the nature of the expense. Indirect costs have been allocated based on the basis of time and effort by employees, and square footage.

##### [13] Income tax uncertainties:

The Institute follows the provisions of the Financial Accounting Standards Board's (the "FASB") Accounting Standards Codification ("ASC") Topic 740, *Income Taxes*, relating to accounting and reporting for uncertainty in income taxes. For the Institute, these provisions could be applicable to the incurrence of unrelated business income. Because of the Institute's general tax-exempt status, management believes ASC Topic 740 has not had, and is not anticipated to have, a material impact on the Institute's financial statements.

##### [14] Net assets:

The net assets of the Institute and changes therein are reported as follows:

(i) *Net Assets Without Donor Restrictions:*

The Institute's net assets without donor restrictions represent those resources that are not subject to donor restrictions as to their use and are available for current operations. Funds designated by the Board of Trustees are to function as an endowment and remain without restrictions, subject to the discretion of the Board of Trustees.

(ii) *Net Assets With Donor Restrictions:*

Net assets with donor restrictions represent those resources that are subject to donor-imposed restrictions, such as specific purposes and/or the passage of time. Also included in net assets with donor restrictions are donor restrictions that are perpetual in nature and are subject to the requirements of the New York Prudent Management of Institutional Funds Act ("NYPMIFA"). These donors have stipulated that those resources be maintained in perpetuity with the resultant income and net capital appreciation arising from the underlying assets to be used in the satisfaction of the wishes of those donors. When a donor's restriction expires, that is, when a stipulated time restriction ends or a purpose restriction is accomplished or a Board appropriation has been made, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as "net assets released from restrictions." Contributions with donor restrictions received in a fiscal period during which the underlying restrictions are also met within the same fiscal period are recorded as net assets without donor restrictions in the statements of activities.

## **CANCER RESEARCH INSTITUTE, INC.**

### **Notes to Financial Statements June 30, 2020 and 2019**

#### **NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

##### **[15] Contributions:**

Contributions to the Institute are recognized as revenue upon the receipt of either cash, other assets, or of unconditional pledges. Contributions are recorded as with donor restrictions if they are received with donor stipulations or time considerations as to their use. Gross proceeds paid by attendees at special events held as fundraising activities represent contribution revenue, as well as the payment of the direct cost of the benefit received by the attendee at the event. Special-event income is reported net of the direct benefit to donors. Special event revenues, other than contributions, applicable to a current year are recognized as revenue in the year the special event takes place. Special event revenue for a future year's period is deferred and recognized when the event takes place. Conditional contributions are recognized when the donor's conditions have been met by requisite actions of the Institute's management or the necessary events have taken place, and if received in advance, are recognized in the statements of financial position as funds received in advance. The Institute records bequest income at the time it has an established right to a bequest and the proceeds are measurable. Contributions to be received over periods longer than a single year are discounted at an interest rate commensurate with the risk involved.

Contributions for clinical studies are recognized and recorded when the Institute recognizes the related expenses associated with the medical partners.

The Institute has entered into various clinical research support agreements to conduct clinical trials of cancer immunotherapies.

The Institute periodically assesses the collectability of its pledges receivable and other receivables using management's judgement regarding potential defaults; accordingly, management considers factors such as: (i) prior collection history; (ii) the type of contributions; and (iii) the nature of the clinical studies/trials, and provided allowances for anticipated losses, if any, when necessary.

##### **[16] Contributed services:**

For recognition of contributed services in the financial statements, such services must: (i) create or enhance non-financial assets, (ii) typically need to be acquired not provided by donation, (iii) require specialized skills and (iv) be provided by individuals possessing these skills. Contributed services are recorded at their estimated fair value at the dates of donation and are reported as without donor restrictions in the statements of activities. The fair values of contributed services provided by the Institute's Scientific Advisory Council totaled \$564,130 and \$484,799 for fiscal-years 2020 and 2019, respectively, and these amounts have been recorded as revenue and expense in the statements of activities. Other contributed services provided to the Institute such as those provided by volunteers, are not reported in the financial statements because they do not meet the criteria for recognition.

##### **[17] Bequests:**

The Institute is a beneficiary under various wills and agreements, the total realizable amounts of which are not presently determinable. The Institute's interest in bequests is recorded as revenue when the Institute receives notice that any such interest has become unconditional.

## CANCER RESEARCH INSTITUTE, INC.

### Notes to Financial Statements June 30, 2020 and 2019

#### NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### [18] Fellowships, investigatorships, and grants:

The Institute awards fellowships, investigatorships, and grants covering periods of one to four years for the purpose of medical research. These awards are recorded as expenses at the time they become unconditional.

##### [19] Science, medical and research information, and communications:

Science, medical and research information, and communications include costs primarily related to: (i) providing the public with information concerning cancer immunology, (ii) responding to inquiries from the public concerning cancer, and (iii) communicating with applicants and awardees. These awards are recorded as expenses at the time they become unconditional.

##### [20] Advertising costs:

The Institute expenses the costs of advertising as incurred. Advertising expenses were \$258,489 and \$397,298 during fiscal-years 2020 and 2019, respectively.

##### [21] Adoption of accounting pronouncements:

(i) *Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made:*

In June 2018, the FASB issued Accounting Standards Update ("ASU") No. 2018-08, *Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made (Topic 985)*. ASU No. 2018-08 clarifies and improves guidance concerning: i) evaluating whether a transaction should be accounted for as an exchange transaction or as a contribution, and ii) determining whether a contribution received is conditional. ASU No. 2018-08 is effective for annual periods beginning after December 15, 2018 for entities that are resource recipients, and periods beginning after December 15, 2019 for entities that are resource providers. The Institute adopted the resource recipient portion of the standard and early adopted the resource provider portion of the standard for the fiscal-year ending June 30, 2020 and this accounting guidance did not have a material effect on the Institute's financial statements.

(ii) *Disclosure Requirements for Fair-Value Measurements:*

In August 2018, the FASB issued ASU No. 2018-13, *Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements*, which modified the disclosure requirements for fair value measurements and is effective for years beginning after December 15, 2019, with early adoption permitted. The effect of adopting this accounting guidance will result in the removal or modification of certain fair value measurement disclosures presented in the Institute's financial statements. The Institute early adopted this pronouncement as of June 30, 2020, which under U.S. GAAP, is a change in accounting principle requiring retroactive application in the financial statements for all periods presented. Analysis of this standard resulted in no significant changes in the Institute's disclosure requirements for fair value measurements, and therefore no changes to the previously issued audited financial statements was required on a retrospective basis.

## CANCER RESEARCH INSTITUTE, INC.

### Notes to Financial Statements June 30, 2020 and 2019

#### NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### [22] Upcoming accounting pronouncements:

(i) *Revenue from Contracts with Customers:*

In May 2014, the FASB issued ASU No. 2014-09, *Revenue from Contracts with Customers (Topic 606)*, which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU No. 2014-09 requires an entity to recognize revenue depicting the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard permits the use of either the retrospective or cumulative effect transition method. The adoption of ASU No. 2014-09 is not expected to have a material effect on the financial statements, but will require enhanced disclosures. The new standard is effective for fiscal years beginning after December 15, 2019. Management is in the process of assessing the impact of this ASU on the financial statements and related disclosures.

(ii) *Leases:*

In February 2016, the FASB issued ASU No. 2016-02, *Leases (Topic 842)*, which will require entities to recognize lease assets and lease liabilities (related to leases previously classified as operating under previous U.S. GAAP) on the statements of financial position. The ASU will be effective for fiscal years beginning after December 15, 2021. Management is in the process of assessing the impact of this ASU on the financial statements and related disclosures.

(iii) *Contributed Nonfinancial Assets*

In September 2020, the FASB issued ASU No. 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*, intended to improve transparency in the reporting of contributed nonfinancial assets, also known as gifts-in-kind, for not-for-profit organizations. The ASU requires a not-for-profit organization to present contributed nonfinancial assets as a separate line item in the statement of activities, apart from contributions of cash or other financial assets. For each category of contributed nonfinancial assets recognized, the not-for-profit organization will need to disclose: (i) qualitative information about whether the contributed nonfinancial assets were either monetized or utilized during the reporting period. If utilized, a description of the programs or other activities in which those assets were used; (ii) the not-for-profit's policy (if any) about monetizing rather than utilizing contributed nonfinancial assets; (iii) a description of any donor-imposed restrictions associated with the contributed nonfinancial assets; (iv) the valuation techniques and inputs used to arrive at a fair value measure, in accordance with the requirements in Topic 820, *Fair Value Measurement*, at initial recognition; and (v) the principal market (or most advantageous market) used to arrive at a fair value measure, if it is a market in which the recipient entity is prohibited by a donor-imposed restriction from selling or using the contributed nonfinancial assets. The amendments in this ASU will be applied on a retrospective basis and are effective for annual reporting periods beginning after June 15, 2021.

##### [23] Subsequent events:

The Institute evaluated subsequent events through November 5, 2020, the date on which the financial statements were available to be issued.

## CANCER RESEARCH INSTITUTE, INC.

### Notes to Financial Statements June 30, 2020 and 2019

#### NOTE B - CONTRIBUTIONS AND GRANTS AND OTHER RECEIVABLES

##### [1] Contributions and grants receivable:

At each fiscal year-end, contributions and grants receivable are estimated to be received as follows:

	<u>June 30,</u>	
	<u>2020</u>	<u>2019</u>
Gross amounts due in:		
Less than one year	<b>\$ 18,225,855</b>	\$ 15,544,043
One to five years	<b><u>20,575,609</u></b>	<u>26,305,137</u>
	<b>38,801,464</b>	41,849,180
Reduction for contributions due in excess of one year, at a 1% discount rate	<b><u>(377,209)</u></b>	<u>(528,106)</u>
	<b>38,424,255</b>	41,321,074
Allowance for uncollectible accounts	<b><u>(1,000,000)</u></b>	<u>(500,000)</u>
	<b><u>\$ 37,424,255</u></b>	<b><u>\$ 40,821,074</u></b>

An amount of \$28,883,349 of the outstanding pledge receivable balance at June 30, 2020, representing approximately 74%, was due from three donors. Likewise, \$33,785,720 of the outstanding pledge receivable balance at June 30, 2019, representing 81%, was due from three donors. Included in contribution revenue for fiscal-years 2020 and 2019, was an amount of \$5,917,456 from one donor and \$17,634,069 from two donors, respectively, which represented approximately 15% and 40%, respectively, of the total operating support and revenue for each fiscal year.

##### [2] Bequest receivables:

Bequests receivable were \$86,665 and \$330,714 as of June 30, 2020 and June 30, 2019, respectively. All amounts are due within one year. All amounts are due within one year. Based on management's past experience the receivables are expected to be fully collected, and, accordingly no allowance for doubtful accounts has been established.

##### [3] Other receivables:

At each year-end, other receivables consisted of amounts due to the Institute for exchange-type transactions. All amounts are due within one year. Based on management's past experience, these receivables are expected to be fully collected, and, accordingly, no allowance for doubtful accounts has been established.



# CANCER RESEARCH INSTITUTE, INC.

## Notes to Financial Statements June 30, 2020 and 2019

### NOTE C - INVESTMENTS

At each fiscal year-end, investments consisted of the following:

	June 30,			
	2020		2019	
	Fair Value	Cost	Fair Value	Cost
Cash equivalents	\$ 3,803,480	\$ 3,803,480	\$ 804,204	\$ 804,204
Equity securities	3,529,270	3,270,624	2,346,778	2,066,086
Mutual funds - equity securities	2,273,144	1,867,361	2,532,715	2,213,996
Mutual funds - fixed-income	2,028,550	1,876,641	3,052,722	2,981,745
Exchange traded funds	5,054,056	4,815,327	5,354,111	4,889,210
Limited partnerships [a]	<u>41,460,698</u>	<u>28,540,809</u>	<u>43,320,002</u>	<u>30,116,006</u>
	<u>\$ 58,149,198</u>	<u>\$ 44,174,242</u>	<u>\$ 57,410,532</u>	<u>\$ 43,071,247</u>

[a] The limited partnerships consist of hedge funds, private equities, and fund-of-funds that primarily invest in domestic and international securities, derivative contracts, and other investments across various classes, sectors, and geographies.

At June 30, 2020 and 2019, concentrations of the Institute's investments in excess of 10% of the fair value of its portfolio included approximately 71% and 75%, respectively, invested in limited partnerships.

During each fiscal year, the net investment return from investments and its classification in the accompanying statements of activities was as follows:

	Year Ended June 30,	
	2020	2019
Interest and dividends	\$ 603,256	\$ 398,949
Net realized and unrealized gains	979,792	2,578,661
Investment advisory fees	<u>(446,545)</u>	<u>(316,293)</u>
	1,136,503	2,661,317
Less: Net investment allocation for current operations	<u>(2,901,985)</u>	<u>(2,586,550)</u>
Net investment income in excess of investment allocation	<u>\$ (1,765,482)</u>	<u>\$ 74,767</u>

# CANCER RESEARCH INSTITUTE, INC.

## Notes to Financial Statements June 30, 2020 and 2019

### NOTE C - INVESTMENTS (CONTINUED)

The FASB's ASC Topic 820, *Fair Value Measurements*, establishes a three-level valuation hierarchy of fair-value measurements. These valuation techniques are based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. These two types of inputs create the following fair-value hierarchy:

- Level 1: Valuations are based on observable inputs that reflect quoted market prices in active markets for identical investments, at the reporting date.
- Level 2: Valuations are based on (i) quoted prices for similar investments in active markets, or (ii) quoted prices for those investments, or similar investments, in markets that are not active, or (iii) pricing inputs other than quoted prices that are directly or indirectly observable at the reporting date.
- Level 3: Valuations are based on pricing inputs that are unobservable and include situations where (i) there is little, if any, market activity for the investments, or (ii) the investments cannot be independently valued.

Certain of the Institute's investments are valued using NAV per share (or its equivalent unit) as a practical expedient of fair value. This applies to investments (i) which do not have a readily determinable fair value; and (ii) the financial statements of which were prepared by the respective investment managers, in a manner consistent with the measurement principles of either an investment company or an entity which has the attributes of an investment company. Investments that are valued using NAV per share (or its equivalent unit) are not required to be categorized within the fair-value hierarchy, and accordingly, these NAV-investments have been appropriately excluded from the fair-value hierarchy.

The availability of relevant market data is monitored by the Institute's management to assess the appropriate classification of financial instruments within the fair-value hierarchy. Changes in economic conditions or valuation techniques may require the transfer of financial instruments from one level to another. In such instances, the transfer is reported at the beginning of the reporting period.

The following tables summarize the fair values of the Institute's investments and other assets at each fiscal year-end, in accordance with ASC Topic 820 valuation fair-value levels:

	June 30, 2020				
	Amounts Within Fair Value Hierarchy			Measured at	
	Level 1	Level 3	Total	NAV	Total
<b>Investments:</b>					
Cash equivalents	\$ 3,803,480	\$ -	\$ 3,803,480	\$ -	\$ 3,803,480
Equity securities	3,529,270	-	3,529,270	-	3,529,270
Mutual funds – equity securities	2,273,144	-	2,273,144	-	2,273,144
Mutual funds - fixed-income	2,028,550	-	2,028,550	-	2,028,550
Mutual funds - ETFs	5,054,056	-	5,054,056	-	5,054,056
Limited partnerships	-	591,118	591,118	40,869,580	41,460,698
	<u>16,688,500</u>	<u>591,118</u>	<u>17,279,618</u>	<u>40,869,580</u>	<u>58,149,198</u>
<b>Other assets:</b>					
Beneficial interest in perpetual trust	-	653,814	653,814	-	653,814
Total	<u>\$ 16,688,500</u>	<u>\$ 1,244,932</u>	<u>\$ 17,933,432</u>	<u>\$ 40,869,580</u>	<u>\$ 58,803,012</u>

**CANCER RESEARCH INSTITUTE, INC.**

**Notes to Financial Statements  
June 30, 2020 and 2019**

**NOTE C - INVESTMENTS (CONTINUED)**

	June 30, 2019				
	Amounts Within Fair Value Hierarchy			Measured at NAV	Total
	Level 1	Level 3	Total		
<b>Investments:</b>					
Cash equivalents	\$ 804,204	\$ -	\$ 804,204	\$ -	\$ 804,204
Equity securities	2,346,778	-	2,346,778	-	2,346,778
Mutual funds – equity securities	2,532,715	-	2,532,715	-	2,532,715
Mutual funds - fixed-income	3,052,722	-	3,052,722	-	3,052,722
Mutual funds - ETFs	5,354,111	-	5,354,111	-	5,354,111
Limited partnerships	-	955,981	955,981	42,364,021	43,320,002
	14,090,530	955,981	15,046,511	42,364,021	57,410,532
<b>Other assets:</b>					
Beneficial interest in perpetual trust	-	656,339	656,339	-	656,339
Total	<u>\$ 14,090,530</u>	<u>\$ 1,612,320</u>	<u>\$ 15,702,850</u>	<u>\$ 42,364,021</u>	<u>\$ 58,066,871</u>

During fiscal-years 2020 and 2019, the Institute purchased approximately \$216,191 and \$84,880 of Level 3 investments, respectively. During fiscal-years 2020 and 2019, the Institute redeemed approximately \$504,455 and \$353,292 of Level 3 investments, respectively.

The following table lists investments in other investment companies by major category at June 30, 2020:

	Fair Value	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Private equity funds	\$ 16,747,702	\$ 12,746,900	N/A	Upon liquidation
Multiple hedge funds	3,394,225	-	Quarterly	30-60 Days
Multiple hedge fund	4,891,332	-	Monthly	30-90 Days
Fund-of-funds	11,312,991	-	Quarterly	95 Days
Fund-of-funds	5,114,448	-	Monthly	95 Days
	<u>\$ 41,460,698</u>	<u>\$ 12,746,900</u>		

## CANCER RESEARCH INSTITUTE, INC.

### Notes to Financial Statements June 30, 2020 and 2019

#### NOTE C - INVESTMENTS (CONTINUED)

Quantitative information regarding unobservable inputs developed by the Institute and assumptions used to measure the investments in limited partnerships, and the beneficial interest in perpetual trust as of June 30, 2020 are as follows:

Type	Fair Value	Valuation Techniques	Significant Unobservable Inputs	Range
Limited partnerships	\$ 591,118	Market approach through valuation of underlying securities	Fair value of trust investment assets	N/A
Beneficial interest in perpetual trust	\$ 653,814	Market approach through valuation of underlying securities	Fair value of trust assets	N/A

The Institute is the irrevocable beneficiary of a perpetual trust, which has been established by a donor to provide income to the Institute with income in perpetuity. At June 30, 2020 and 2019, the fair value of this trust was \$653,814 and \$656,339, respectively.

#### NOTE D - PROPERTY AND EQUIPMENT

At each fiscal year-end, property and equipment consisted of the following:

	June 30,	
	2020	2019
Office equipment	\$ 499,658	\$ 486,061
Leasehold improvements	<u>91,569</u>	<u>91,569</u>
	591,227	577,630
Less accumulated depreciation and amortization	<u>(428,647)</u>	<u>(388,734)</u>
	<u>\$ 162,580</u>	<u>\$ 188,896</u>

During fiscal-year 2019, the Institute disposed of fully depreciated assets that were no longer in service with a cost basis of \$7,860.

## CANCER RESEARCH INSTITUTE, INC.

### Notes to Financial Statements June 30, 2020 and 2019

#### NOTE E - PPP LOAN PAYABLE

On March 27, 2020, Congress enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The PPP, established by the CARES Act, and implemented by the SBA, provides businesses, including certain not-for-profit organizations, with funds to pay payroll and others costs during Coronavirus (“COVID-19”) outbreak, further disclosed in Note N. On May 1, 2020, the Institute received \$710,150 in funds from the PPP and is reported as a Paycheck Protection Program loan payable in the statement of financial position at June 30, 2020. Neither principle nor interest is due for a six-month deferral period through November 2020. This loan may be forgiven subject to bank approval in accordance with SBA guidelines. Any outstanding principle of the loan that is not forgiven under the PPP Loan program at the end of the six-month deferral period will convert to a term loan with an interest rate of 1% payable in equal installments of principle and interest over the next eighteen months, beginning in December 2020. The loan matures May 1, 2022. The Institute is in the process of applying for forgiveness. Until determination of forgiveness, the scheduled future principle maturities as of June 30, 2020 are as follows:

<u>Fiscal-Year Ending June 30,</u>	<u>Amount</u>
2021	\$ 276,170
2022	<u>433,980</u>
Total	<u>\$ 710,150</u>

#### NOTE F - GRANTS AND FELLOWSHIPS PAYABLE

At each fiscal year-end, grants and fellowships payable consisted of the following:

	<u>June 30,</u>	
	<u>2020</u>	<u>2019</u>
Due to be paid within one years	\$ 33,193,852	\$ 30,217,434
Due to be paid between two and five years	<u>32,175,165</u>	<u>38,411,546</u>
	65,369,017	68,628,980
Less present value discount of up to 1%	<u>(493,925)</u>	<u>(624,247)</u>
	<u>\$ 64,875,092</u>	<u>\$ 68,004,733</u>

# CANCER RESEARCH INSTITUTE, INC.

## Notes to Financial Statements June 30, 2020 and 2019

### NOTE G - NET ASSETS WITH DONOR RESTRICTIONS

At each fiscal year-end, net assets with donor restrictions consisted of the following:

	<u>June 30,</u>	
	<u>2020</u>	<u>2019</u>
Purpose restricted:		
Clinical and laboratory research	<b>\$ 20,749,144</b>	\$ 20,795,328
Combined federal campaign restricted for future periods	<u>-</u>	<u>100,000</u>
	<b><u>20,749,144</u></b>	<u>20,895,328</u>
Perpetual in nature:		
Fellowships	<b>2,878,390</b>	2,878,390
Other	<b><u>653,814</u></b>	<u>656,339</u>
	<b><u>3,532,204</u></b>	<u>3,534,729</u>
	<b><u>\$ 24,281,348</u></b>	<u>\$ 24,430,057</u>

Included within net assets with donor restrictions for clinical and laboratory research is accumulated endowment income reserved for appropriation at both June 30, 2020 and 2019 of \$237,406.

Net assets released from restrictions during each year were for the following:

	<u>Year Ended June 30,</u>	
	<u>2020</u>	<u>2019</u>
Clinical and laboratory research	<b>\$ 4,231,083</b>	\$ 6,182,458
Combined federal campaign restricted for future periods	<u>100,000</u>	<u>195,660</u>
	<b><u>\$ 4,331,083</u></b>	<u>\$ 6,378,118</u>

**CANCER RESEARCH INSTITUTE, INC.**

**Notes to Financial Statements  
June 30, 2020 and 2019**

**NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS**

**[1] The endowment:**

The Institute's endowment funds consists of individual funds established for a variety of purposes, consisting of both donor-restricted and Board-designated funds. As required by U.S. GAAP, net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

**[2] Interpretation of relevant law:**

As discussed in Note A[14] (ii), NYPMIFA is applicable to all of the Institute's institutional funds, including its donor-restricted endowment funds. The Board of Trustees will continue to adhere to NYPMIFA's requirements.

**[3] Endowment net-asset composition by type of fund, as of each fiscal year-end:**

	<b>June 30, 2020</b>			
	<b>Without Donor Restrictions</b>	<b>Amounts Subject to Appropriation</b>	<b>Amounts Held in Perpetuity</b>	<b>Total</b>
Donor-restricted endowment funds	\$ -	\$ 237,406	\$ 3,532,204	\$ 3,769,610
Board-designated endowment funds	<u>4,539,701</u>	<u>-</u>	<u>-</u>	<u>4,539,701</u>
Total funds	<u>\$ 4,539,701</u>	<u>\$ 237,406</u>	<u>\$ 3,532,204</u>	<u>\$ 8,309,311</u>

  

	<b>June 30, 2019</b>			
	<b>Without Donor Restrictions</b>	<b>Amounts Subject to Appropriation</b>	<b>Amounts Held in Perpetuity</b>	<b>Total</b>
Donor-restricted endowment funds	\$ -	\$ 237,406	\$ 3,534,729	\$ 3,772,135
Board-designated endowment funds	<u>4,428,807</u>	<u>-</u>	<u>-</u>	<u>4,428,807</u>
Total funds	<u>\$ 4,428,807</u>	<u>\$ 237,406</u>	<u>\$ 3,534,729</u>	<u>\$ 8,200,942</u>

**CANCER RESEARCH INSTITUTE, INC.**

**Notes to Financial Statements**  
**June 30, 2020 and 2019**

**NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS (CONTINUED)**

**[4] Changes in endowment net assets, during each fiscal year:**

	Year Ended June 30, 2020			Total
	Without Donor Restrictions	Amounts Subject to Appropriation	Amounts Held in Perpetuity	
Endowment net assets, beginning of year	\$ 4,428,807	\$ 237,406	\$ 3,534,729	\$ 8,200,942
Investment return:				
Investment income	24,726	8,997	-	33,723
Net appreciation (realized and unrealized)	<u>64,468</u>	<u>201,776</u>	<u>(2,525)</u>	<u>263,719</u>
Total investment return	89,194	210,773	(2,525)	297,442
Contributions	21,700	-	-	21,700
Appropriation of endowment assets for expenditure endowment funds	<u>-</u>	<u>(210,773)</u>	<u>-</u>	<u>(210,773)</u>
Endowment net assets, end of year	<u>\$ 4,539,701</u>	<u>\$ 237,406</u>	<u>\$ 3,532,204</u>	<u>\$ 8,309,311</u>

	Year Ended June 30, 2019			Total
	Without Donor Restrictions	Amounts Subject to Appropriation	Amounts Held in Perpetuity	
Endowment net assets, beginning of year	\$ 4,172,232	\$ 237,406	\$ 3,530,059	\$ 7,939,697
Investment return:				
Investment income	24,353	20,917	-	45,270
Net appreciation (realized and unrealized)	<u>198,488</u>	<u>129,509</u>	<u>4,670</u>	<u>332,667</u>
Total investment return	222,841	150,426	4,670	377,937
Contributions	33,734	-	-	33,734
Appropriation of endowment assets for expenditure endowment funds	<u>-</u>	<u>(150,426)</u>	<u>-</u>	<u>(150,426)</u>
Endowment net assets, end of year	<u>\$ 4,428,807</u>	<u>\$ 237,406</u>	<u>\$ 3,534,729</u>	<u>\$ 8,200,942</u>

Amounts subject to appropriation represent that portion of allocated investment income, derived from endowment assets held in perpetuity that has not yet been appropriated for expenditure by the Board of Trustees.



# CANCER RESEARCH INSTITUTE, INC.

## Notes to Financial Statements June 30, 2020 and 2019

### NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS (CONTINUED)

#### [5] Funds with deficiencies:

Due to unfavorable market fluctuations, from time to time, the fair value of assets associated with individual donor-restricted endowment funds may decline below the historic dollar-value of the donor's original restricted contribution to be held in perpetuity. Under the terms of NYPMIFA, the Institute has no responsibility to restore such decreases in value. There were no such deficiencies at June 30, 2020 and 2019.

#### [6] Return objectives and risk parameters:

The Institute has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs and other functions supported by its Board-designated endowment, while seeking to maintain the purchasing power of the Board-designated endowment assets. Under this policy, as approved by the Board of Trustees, the Board-designated endowment assets are invested in a manner that is intended to produce results that obtain a better rate of return than the major investment indexes. The two donor-restricted funds (other than the perpetual trust) generate income that is fully utilized each year for their specified programmatic activities.

#### [7] Strategies employed for achieving objectives:

To satisfy its long-term rate-of-return objectives, the Institute relies on a total-return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Institute targets a diversified asset allocation within prudent risk constraints.

#### [8] Spending policy and related objectives:

##### (i) *Endowment appropriation:*

The appropriation from the endowment is based on the earnings in the respective year.

##### (ii) *Investment pool appropriation:*

The Board of Trustees' authorized spending from the Institute's investment pool (for restricted funds and for general operations) is 5% of the average market value of the Institute's investment portfolio over the preceding three years. In establishing this policy, the Institute considered the long-term expected return on its investment. Accordingly, over the long term, the Institute expects the current spending policy to allow its portfolio to maintain the purchasing power of the Board-designated endowment assets, as well as to provide additional real growth through investment returns.

## CANCER RESEARCH INSTITUTE, INC.

### Notes to Financial Statements June 30, 2020 and 2019

#### NOTE I - LIQUIDITY AND AVAILABILITY OF RESOURCES

The following reflects the Institute's financial assets as of the statement of financial position date, reduced by amounts not available for general use within one year of June 30, 2020 because of contractual or donor-imposed restrictions or internal designations. Amounts not available include amounts set aside by the Board of Trustees for the growth and sustainability of the Institute that could be drawn upon if the Board of Trustees approves the action.

The Institute's financial assets available for general use within one year of the statements of financial position date for general expenditure are as follows:

	<u>Year Ended June 30,</u>	
	<u>2020</u>	<u>2019</u>
Cash and cash equivalents	<b>\$ 29,455,207</b>	\$ 27,429,143
Contributions and grants receivable, net	<b>37,424,255</b>	40,821,074
Bequests receivable	<b>86,655</b>	330,714
Other receivables	<b>233,807</b>	287,139
Investments (net of private placements with redemption restrictions)	<b><u>41,401,496</u></b>	<u>44,406,939</u>
Total financial assets available within one year	<b><u>108,601,420</u></b>	<u>113,275,009</u>
Less:		
Amounts unavailable for general expenditures within one year, due to:		
Restrictions by donors with purpose restrictions	<b>(20,749,144)</b>	(20,895,328)
Restricted by donors that are perpetual in nature	<b><u>(2,878,390)</u></b>	<u>(2,878,390)</u>
Total amounts unavailable for general expenditure within one year	<b><u>(23,627,534)</u></b>	<u>(23,773,718)</u>
Amounts unavailable to management without Board approval:		
Board-designated endowment	<b><u>(4,539,701)</u></b>	<u>(4,428,807)</u>
Total financial assets available to meet cash needs for general expenditures within one year	<b><u>\$ 80,434,185</u></b>	<u>\$ 85,072,484</u>

#### Liquidity policy:

The Institute has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Additionally, the Institute has a Board-designated endowment whereby amounts could be made available for current operations, if necessary; however, the Institute does not intend to spend these funds for purposes other than those approved by the Board of Trustees.

## CANCER RESEARCH INSTITUTE, INC.

### Notes to Financial Statements June 30, 2020 and 2019

#### NOTE J - ALLOCATION OF JOINT COSTS OF INFORMATION MATERIALS

The Institute incurred joint costs in the placement of advertisements that amounted to \$53,153 and \$57,430 in fiscal-years 2020 and 2019, respectively. The Institute allocated such costs as follows:

	<u>June 30,</u>	
	<u>2020</u>	<u>2019</u>
Marketing and development	\$ 41,308	\$ 34,368
Science, medical and research information and communications	<u>13,845</u>	<u>23,062</u>
	<u>\$ 55,153</u>	<u>\$ 57,430</u>

#### NOTE K - EMPLOYEE-BENEFIT PLAN

The Institute has a defined-contribution retirement plan, which provides for the Institute to make monthly contributions of at least 5% of the compensation of eligible employees. In addition, the Institute may contribute to the plan a discretionary amount equal to a percentage of compensation which is to be determined each plan-year by the Institute. The plan also allows the participants to make voluntary contributions up to the maximum allowed by federal tax law. During fiscal-years 2020 and 2019, the Institute contributed amounts of approximately \$297,000 and \$280,000, respectively, to the plan.

#### NOTE L - CREDIT RISK

Financial instruments that potentially subject the Institute to concentrations of credit risk consist principally of cash and cash-equivalents deposited in financial institutions in amounts which, from time to time, may exceed federal insurance limits. However, based on the current Federal Deposit Insurance Coverage, management believes that the Institute does not face a significant risk of loss on these accounts that might result from the failures of the financial institutions.

#### NOTE M - FINANCIAL INVESTMENT

In 2010, the Institute entered into a joint venture with the Ludwig Institute for Cancer Research Ltd. and formed a U.S. company named Cancer Vaccine Acceleration Company, LLC ("CVAC"). The members' initial capital contribution was \$200. The purpose of the company is to obtain, hold, and develop intellectual property and other assets related to research and development of a vaccine for cancer in furtherance of the respective charitable missions of the members. The Institute believes that at present, the value of this investment is not material.

## CANCER RESEARCH INSTITUTE, INC.

### Notes to Financial Statements June 30, 2020 and 2019

#### NOTE N - COMMITMENTS AND OTHER UNCERTAINTY

##### [1] Lease obligation:

The Institute is obligated under a 124-month lease agreement for office space expiring in January 2028. The lease is subject to escalation for the Institute's pro-rata share of increases in real estate taxes and operating expenses. Concurrent with the authorization of the lease agreement, the Institute entered into a sublease agreement for a portion of its office space also expiring in January 2028. In September 2017, the Institute entered into lease agreements for office equipment, which expire in September 2022. Minimum future estimated lease payments and lease income are as follows:

<u>Year Ending June 30,</u>	<u>Lease Payments</u>	<u>Lease Income</u>
2021	\$ 545,756	\$ (126,165)
2022	545,756	(126,165)
2023	554,071	(134,051)
2024	556,842	(136,679)
2025	556,842	(136,679)
Thereafter	<u>1,438,509</u>	(353,087)
Total	<u>\$ 4,197,776</u>	<u>\$ (1,012,826)</u>

##### [2] Other uncertainty:

The extent of the impact and effects of the recent outbreak of COVID-19 on the operation and financial performance of the Institute's business will depend on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, and the consequential potential of staff shortages, all of which are highly uncertain and cannot be predicted. If demands for the Institute's services are impacted for an extended period, the Institute's results of operations may be materially adversely affected.